Levepsy XR 500 Tablet contains Levetiracetam 500mg, an antiepileptic medication indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby inhibiting abnormal neuronal excitability and seizure propagation. The extended-release formulation of Levepsy XR allows for once-daily dosing, enhancing patient compliance by maintaining stable plasma drug concentrations over 24 hours. It is recommended to initiate therapy at a low dose with gradual titration based on clinical response and tolerability. Common adverse effects include somnolence, dizziness, headache, and fatigue, which are generally mild to moderate and transient. Levepsy XR should be used cautiously in patients with renal impairment, and dose adjustments may be necessary. It is contraindicated in individuals with known hypersensitivity to Levetiracetam or any of the excipients. Concomitant use with other antiepileptic drugs should be monitored for potential pharmacodynamic interactions. Levepsy XR 500 Tablet is intended to be used under strict medical supervision as part of a comprehensive epilepsy management plan to reduce seizure frequency and improve quality of life.